Data investigation
The First Pill-Versus-Pill Trial
Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.
ACHIEVE-3 put two oral GLP-1s directly against each other in 1,698 adults with type 2 diabetes, and orforglipron beat oral semaglutide on blood sugar at every dose pairing tested, including the low orforglipron dose against the high semaglutide dose.[1] It also produced more gastrointestinal side effects, roughly double the dropouts, and a larger rise in resting heart rate. Both halves are the result.
What the trial did
Adults with type 2 diabetes inadequately controlled on at least 1,500 mg of metformin daily, with an HbA1c between 7.0% and 10.5% and a BMI of 25 or above, were randomized in equal quarters to orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, or oral semaglutide 14 mg, and followed for 52 weeks across 131 centers in Argentina, China, Japan, Mexico and the United States. Baseline HbA1c averaged 8.3%. The trial doses are not the strengths on the Foundayo label: Lilly’s later ACHIEVE-4 paper states that a 36 mg capsule dose is equivalent to the 17.2 mg tablet.[2]
The design first asked whether orforglipron could match semaglutide within 0.3% (non-inferiority), and tested superiority only if that was met. It was met, and superiority followed.
| Arm | HbA1c change | vs semaglutide 7 mg | vs semaglutide 14 mg |
|---|---|---|---|
| Orforglipron 12 mg | −1.71% | −0.48% (−0.65 to −0.31), p<0.0001 | −0.24% (−0.41 to −0.072), p=0.0050 |
| Orforglipron 36 mg | −1.91% | −0.68% (−0.85 to −0.50), p<0.0001 | −0.44% (−0.62 to −0.26), p<0.0001 |
| Oral semaglutide 7 mg | −1.23% | — | — |
| Oral semaglutide 14 mg | −1.47% | — | — |
Look at the first row, last column: the low dose of orforglipron beat the high dose of semaglutide, by 0.24 percentage points. The difference is modest but meaningful, because it is the comparison a formulary makes when deciding what to put where.
The design problem this particular pair creates
That creates a route to the result that is not pharmacology. Semaglutide’s blood level depends on a daily ritual being performed correctly; orforglipron’s does not. A gap of 0.24 to 0.68 percentage points could reflect the molecule, or the fasting window, or both, and a trial where participants know their assignment cannot separate them.
We are not claiming that is what happened. We are saying the trial cannot tell you, and that this ambiguity matters more here than in an ordinary head-to-head. The ambiguity also has a second side. If convenience is part of why orforglipron did better, that is still a real advantage to a real patient, just not the advantage the word “superior” implies.
The cost side of the result
Gastrointestinal events hit 59% of the orforglipron 12 mg arm and 58% of the 36 mg arm, against 37% on semaglutide 7 mg and 45% on 14 mg. Most were mild to moderate. The consequential number is what people did about them.
| Orfo 12 mg | Orfo 36 mg | Sema 7 mg | Sema 14 mg | |
|---|---|---|---|---|
| Gastrointestinal events | 59% | 58% | 37% | 45% |
| Stopped due to adverse events | 9% | 10% | 4% | 5% |
| Mean pulse increase | +3.7 bpm | +4.7 bpm | +1.0 bpm | +1.5 bpm |
Roughly twice as many people quit orforglipron because of side effects. That is part of the finding, not a footnote to it.
The pulse difference deserves its own sentence. A rise in resting heart rate is a known class effect, but here it was more than three times larger with orforglipron than with oral semaglutide at the paired doses. Why a GLP-1 raises your heart rate covers what the labels say about it. In a population with type 2 diabetes and a mean BMI above 25, that is a variable a cardiologist would want to know about, and it has no bearing on the HbA1c headline whatsoever.
Four deaths occurred across the trial: one in each orforglipron arm and two on semaglutide 7 mg. With 1,698 participants over a year, that is not a signal in either direction.
What this does not tell you
- It is not a weight-loss trial. The endpoint was HbA1c in people with type 2 diabetes on metformin. Orforglipron’s obesity evidence is a separate trial with a separate design, and reading a diabetes HbA1c result as a weight result is the error this register calls out in sellers.
- The comparator was 7 and 14 mg oral semaglutide, not the higher 25 and 50 mg strengths. A different comparator arm could produce a different gap.
- Eli Lilly funded it, and Eli Lilly makes orforglipron. The comparator is a Novo Nordisk product. That does not invalidate a Lancet phase 3 trial; it is context every reader of an industry head-to-head is entitled to.
- Fifty-two weeks is not a long time for a chronic condition, and nothing here speaks to cardiovascular or kidney outcomes. Orforglipron now has a cardiovascular safety trial: ACHIEVE-4 compared it with insulin glargine and found its rate of serious cardiovascular events inside the prespecified safety margin (hazard ratio 0.84, 95% CI 0.59 to 1.20).[2] That rules out a large harm. It is not the outcome benefit semaglutide has shown.
- Orforglipron is not approved for type 2 diabetes. In the US it is sold as Foundayo for weight management only. Lilly has submitted the diabetes indication to the FDA, and no decision has been announced.[3]
For what orforglipron is and how it is labeled, see Foundayo. For the drugs still behind it, see the oral pipeline, and for how side-effect burden compares across the class generally, see which GLP-1 has the worst side effects.
Frequently Asked Questions
References
- 1.Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial The Lancet. 2026. PMID: 41765029.
- 2.Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial The Lancet. 2026. PMID: 42815506.
- 3.Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K, Exhibit 99.1) — regulatory progress includes the submission for orforglipron for type 2 diabetes in the U.S. U.S. Securities and Exchange Commission (EDGAR). 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm
Compare the sellers
Related research
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
7 min read
The Statistic That Asks If Groups Differ
A SOUL secondary analysis found oral semaglutide cutting heart-failure events in people who had heart failure and doing nothing in those who did not. The test of whether that split is real came out at P = .06.
7 min read
The Dose That Stopped Helping
ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.
6 min read
An Oral Pill in a Diabetes Population
Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.
7 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
Antipsychotics and Metabolic Harm
The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →